The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review
- 1.9k Downloads
Crohn’s disease (CD) is associated with a substantial healthcare burden that affects the patient, healthcare systems and society in general.
To provide a systematic evaluation of published data relating to the economic and health-related quality-of-life (HRQoL) burden of CD in selected European countries (Germany, France, UK, Italy, Spain) and the USA since 2000.
We undertook a systematic review of publications relating to CD, its economic burden and impact on HRQoL. Research questions focused on the disease costs from a societal perspective and HRQoL burden in adults and pediatric/adolescent patients according to disease stage/severity. Total, direct and indirect costs were identified, as well as the impact of CD on HRQoL measured using both generic and disease-specific instruments.
Overall, 61 publications met the research criteria (38 on costs, 23 on HRQoL). CD in the USA and Europe together was associated with annual total costs of nearly €30 billion, more than half due to indirect costs. HRQoL was consistently and statistically significantly lower among CD patients compared with normal populations, due to physical, emotional and social effects.
CD is a global health problem with high societal costs and substantial HRQoL burden. High-value care pathways including cost-effective therapies will help to induce and maintain remission, reduce complications of disease and improve HRQoL.
KeywordsCrohn’s disease Epidemiology Prevalence Incidence Cost burden Quality of life Quality-of-life burden
Conflict of interest
DF: employed by PHMR: PHMR received an unrestricted grant from Nestlé Health Science S.A. to perform the systematic literature search. SL: employed by PHMR: PHMR received an unrestricted grant from Nestlé Health Science S.A. to perform the systematic literature search. HS: previous employee of Nestle Health Sciences. BGL: Received consulting fees from Prometheus Labs, Santarus Inc., and Nestle Health Sciences, Abbvie and Takeda.
- 8.National Institute for Health and Clinical Excellence (NICE). Crohn’s Disease. Management in Adults and Children. London: NICE; 2012.Google Scholar
- 18.Benedini V, Caporaso N, Corazza GR, et al. Burden of Crohn’s disease: economics and quality of life aspects in Italy. Clin Outcomes Res. 2012;4:209–218.Google Scholar
- 39.Bastida G, Nos P, Aguas M, et al. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol. 2010;10:26.Google Scholar
- 46.Piche T, Ducrotte P, Sabate JM, et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:626+e174–632+e174.Google Scholar
- 52.Khanna R, Levesque BG, Bressler B, et al. Early Combined Immunosuppression for the Management of Crohn’s Disease: A Community-Based Cluster Randomized Trial. Copenhagen: ECCO; 2014 [Abstract OP004].Google Scholar